Clinical trials: DSA
Anesthesia, Depth of Hypnosis Monitoring
The Effect of DSA on Recovery of Anaesthesia in Children
In this randomised, blinded study, we will investigate the influence of DSA on recovery from general anaesthesia. DSA monitoring provides continuous information on depth of hypnosis.
- Trial name
- DSA-RCT-1 (NCT05525104)
- Testing
- Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)
- Where
- Netherlands
- Volunteers
- 112 people
- Sponsor
- Erasmus Medical Center
End Stage Renal Disease (ESRD)
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
In this Phase I/II trial, 10 highly sensitized patients will be entered after informed consent and will receive Intravenous Immunoglobulin (IVIG) at 2 gm/kg + Tocilizumab 8 mg/kg x 5 doses on days 15, 45, 75, 105, 119, 135, and…
- Trial name
- NCT01594424
- Testing
- Tocilizumab, Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Peripheral Arterial Occlusive Disease
Isovue in Peripheral Digital Subtraction Angiography (DSA)
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
- Trial name
- NCT01075217
- Testing
- iopamidol, iodixanol
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Bracco Diagnostics, Inc
Peripheral Arterial Disease (PAD)
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries.
- Trial name
- NCT00707876
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Kidney Transplantation in Highly Sensitized Patients
A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in…
- Trial name
- NCT05049850
- Testing
- Imlifidase
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hansa Biopharma AB
Peripheral Arterial Occlusive Disease
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.
- Trial name
- NCT00740207
- Testing
- VISIPAQUE 270, Isovue 250
- Volunteers
- 33 people
- Sponsor
- Bracco Diagnostics, Inc
Transplant; Failure, Kidney
Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
- Trial name
- NCT01044303
- Testing
- Myfortic Escalation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- East Carolina University
Kidney Transplantation
Efficacy of Belatacept in Reducing DSA
The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).
- Trial name
- NCT02078193
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- East Carolina University
Kidney Transplantation
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants…
- Trial name
- ASTOUND (NCT02723591)
- Testing
- Tacrolimus, Tacrolimus immediate release
- Where
- 30 sites in United States
- Volunteers
- 599 people
- Sponsor
- Astellas Pharma Global Development, Inc.